Postprocedural Management: Anticoagulation and Beyond
- PMID: 32067650
- DOI: 10.1016/j.ccep.2019.10.002
Postprocedural Management: Anticoagulation and Beyond
Abstract
Excluding the left atrial appendage in patients with nonvalvular atrial fibrillation is a mechanical way to decrease stroke risk. During endothelialization, the closure device is exposed to circulating blood, which might activate the coagulation cascade. In excessive proportions, possibly resulting in the development of device-related thrombus, requiring a bridging period with optimal antithrombotic treatment. Initial protocol treatment is less suitable for patients with contraindications to anticoagulation. Less intensive antithrombotic regimens investigated suggest safety and efficacy, however further research is required. A tailored treatment, considering bleeding and thromboembolic risk based on patient/procedural characteristics in every patient, is probably the best approach.
Keywords: Anti-platelet therapy; Device related thrombus; Left atrial appendage closure; Oral anticoagulation; Stroke; Thromboembolic complications.
Copyright © 2019 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure M. Maarse, has no conflicts of interest to declare. L.V.A. Boersma is a consultant for Boston Scientific and proctor for Abbott. M.J. Swaans reports proctoring fees for training/educational services to the Department of Cardiology from Boston Scientific, and personal fees from Abbott, Philips Healthcare and Bioventrix Inc.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
